Loading...
Market
What will be NTLA-2002's market share in HAE treatment by end of 2026?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Market analysis reports and pharmaceutical sales data
Story
Intellia Therapeutics Initiates HAELO Phase 3 Trial of NTLA-2002, a CRISPR Treatment for HAE
Oct 7, 2024, 11:33 AM
Intellia Therapeutics announced the initiation of HAELO, a global, 60-patient Phase 3 study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for hereditary angioedema (HAE). NTLA-2002 aims to disrupt the HAE market by potentially offering a one-time treatment solution. Compared to current prophylactic drugs such as lanadelumab and berotralstat, which cost approximately $500,000 annually, NTLA-2002 is expected to cost a fraction over a lifetime, even at a projected price of $3 million. The treatment boasts best overall efficacy and eliminates the need for repeated administrations, potentially improving patient quality of life. The initiation comes ahead of the upcoming Phase 2 data presentation at the American College of Allergy, Asthma & Immunology (ACAAI), which could significantly catalyze enrollment in the study.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%